Corrigendum to “Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests” [J Microbiol Immunol Infect (2015) 924–933](S1684118215008191)(10.1016/j.jmii.2015.06.009);Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests

Journal of Microbiology, Immunology and Infection

Volumn 49, Issue 6, 2016, Pages 924-933

  Jean, Shio Shin ^a   Hsieh, Tai Chin ^a   Hsu, Chin Wan ^a   Lee, Wen Sen ^a   Bai, Kuan Jen ^a   Lam, Carlos ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

combination regimen; extensively drug resistant Acinetobacter baumannii; imipenem; sulbactam; tigecycline; ventilator associated pneumonia

Indexed keywords

CILASTATIN PLUS IMIPENEM; IMIPENEM; SULBACTAM; TIGECYCLINE; ANTIINFECTIVE AGENT; CILASTATIN; CILASTATIN, IMIPENEM DRUG COMBINATION; DRUG COMBINATION; MINOCYCLINE;

ACINETOBACTER INFECTION; ADULT; AGED; ARTICLE; BACTERIUM ISOLATE; BURKHOLDERIA CEPACIA; CASE FATALITY RATE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY RATE; NONHUMAN; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; RASH; SURVIVAL RATE; TRACHEAL ASPIRATION PROCEDURE; VENTILATOR ASSOCIATED PNEUMONIA; VOMITING; ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANALOGS AND DERIVATIVES; BACTEREMIA; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; HOSPITAL MORTALITY; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; PNEUMONIA, VENTILATOR-ASSOCIATED; PROCEDURES; SALVAGE THERAPY; TAIWAN; TREATMENT OUTCOME; VERY ELDERLY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; CILASTATIN; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HOSPITAL MORTALITY; HUMANS; IMIPENEM; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MINOCYCLINE; PNEUMONIA, VENTILATOR-ASSOCIATED; SALVAGE THERAPY; SULBACTAM; TAIWAN; TREATMENT OUTCOME;

EID: 84940705768     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2017.01.002     Document Type: Erratum

References (43)

1. 1 American Thoracic Society; Infectious Diseases Society of America, Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171 (2005), 388–416.
2. 2 Chuang, Y.C., Sheng, W.H., Li, S.Y., Lin, Y.C., Wang, J.T., Chen, Y.C., et al. Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with Acinetobacter bacteremia. Clin Infect Dis 52 (2011), 352–360.
3. 3 Lee, N.Y., Chang, T.C., Wu, C.J., Chang, C.M., Lee, H.C., Chen, P.L., et al. Clinical manifestations, antimicrobial therapy, and prognostic factors of monomicrobial Acinetobacter baumannii complex bacteremia. J Infect 61 (2010), 219–227.
4. 4 Ku, W.W., Kung, C.H., Lee, C.H., Tseng, C.P., Wu, P.F., Kuo, S.C., et al. Evolution of carbapenem resistance in Acinetobacter baumannii: an 18-year longitudinal study from a medical center in northern Taiwan. J Microbiol Immunol Infect 48 (2015), 57–64.
5. 5 Jean, S.S., Hsueh, P.R., Lee, W.S., Yu, K.W., Liao, C.H., Chang, F.Y., et al. Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan: results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009. Int J Antimicrob Agents 41 (2013), 457–462.
6. 6 Ko, W.C., Lee, H.C., Chiang, S.R., Yan, J.J., Wu, J.J., Lu, C.L., et al. In vitro and in vivo activity of meropenem and sulbactam against a multidrug-resistant Acinetobacter baumannii strain. J Antimicrob Chemother 53 (2004), 393–395.
7. 7 Hsueh, P.R., Teng, L.J., Chen, C.Y., Chen, W.H., Yu, C.J., Ho, S.W., et al. Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan. Emerg Infect Dis 8 (2002), 827–832.
8. 8 Lodise, T.P., Sorgel, F., Melnick, D., Mason, B., Kinzig, M., Drusano, G.L., Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 55 (2011), 1606–1610.
9. 9 Drusano, G.L., Lodise, T.P., Melnick, D., Liu, W., Oliver, A., Mena, A., et al. Meropenem penetration into epithelial lining fluid in mice and humans and delineation of exposure targets. Antimicrob Agents Chemother 55 (2011), 3406–3412.
10. 10 Lee, N.Y., Wang, C.L., Chuang, Y.C., Yu, W.L., Lee, H.C., Chang, C.M., et al. Combination carbapenem–sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study. Pharmacotherapy 27 (2007), 1506–1511.
11. 11 Lee, C.M., Lim, H.K., Liu, C.P., Tseng, H.K., Treatment of pan-drug resistant Acinetobacter baumannii. Scand J Infect Dis 37 (2005), 195–199.
12. 12 Petersen, P.J., Labthavikul, P., Jones, C.H., Bradford, P.A., In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother 57 (2006), 573–576.
13. 13 White, R.L., Burgess, D.S., Manduru, M., Bosso, J.A., Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob Agents Chemother 40 (1996), 1914–1918.
14. 14 Horan, T.C., Gaynes, R.P., Surveillance of nosocomial infections. Mayhall, C.G., (eds.) Hospital epidemiology and infection control, 3rd ed, 2004, Lippincott Williams & Wilkins, Philadelphia, 1659–1702.
15. 15 FDA, FDA drug safety communication: Increased risk of death of tygacil (tigecycline) compared to other antibiotics to treat similar infections. 2010 [Accessed 15 March 2015] http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm.
16. 16 Charlson, M.E., Pompei, P., Ales, K.L., MacKenzie, C.R., A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (1987), 373–383.
17. 17 Knaus, W.A., Zimmerman, J.E., Wagner, D.P., Draper, E.A., Lawrence, D.E., APACHE–acute physiology and chronic health evaluation: a physiology based classification system. Crit Care Med 9 (1981), 591–597.
18. 18 Chow, J.W., Yu, V.L., Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Int J Antimicrob Agents 11 (1999), 7–12.
19. 19 Pugin, J., Auckenthaler, R., Mili, N., Janssens, J.P., Lew, P.D., Suter, P.M., Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic “blind” bronchoalveolar lavage fluid. Am Rev Respir Dis 143 (1991), 1121–1129.
20. 20 Bellomo, R., Ronco, C., Kellum, J.A., Mehta, R.L., Palevsky, P., Acute Dialysis Quality Initiative workgroup. Acute renal failure — definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8 (2004), R204–R212.
21. 21 Ashbaugh, D.G., Bigelow, D.B., Petty, T.L., Levine, B.E., Acute respiratory distress in adults. Lancet 2 (1967), 319–323.
22. 22 Pittet, D., Tarara, D., Wenzel, R.P., Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA 271 (1994), 1598–1601.
23. 23 Lin, Y.C., Sheng, W.H., Chang, S.C., Wang, J.T., Chen, Y.C., Wu, R.J., et al. Application of a microsphere-based array for rapid identification of Acinetobacter spp. with distinct antimicrobial susceptibilities. J Clin Microbiol 46 (2008), 612–617.
24. 24 Clinical and Laboratory Standards Institute (CLSI), Performance standards for antimicrobial susceptibility testing; Twenty-third informational supplement. M100-S23, 2013, CLSI, Wayne, PA.
25. 25 Jones, R.N., Ferraro, M.J., Reller, L.B., Schreckenberger, P.C., Swenson, J.M., Sader, H.S., Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J Clin Microbiol 45 (2007), 227–230.
26. 26 Pitout, J.D., Gregson, D.B., Poirel, L., McClure, J.A., Le, P., Church, D.L., Detection of Pseudomonas aeruginosa producing metallo-β-lactamase in a large centralized laboratory. J Clin Microbiol 43 (2005), 3129–3135.
27. 27 Chuang, Y.C., Sheng, W.H., Lauderdale, T.L., Li, S.Y., Wang, J.T., Chen, Y.C., et al. Molecular epidemiology, antimicrobial susceptibility and carbapenemase resistance determinants among Acinetobacter baumannii clinical isolates in Taiwan. J Microbiol Immunol Infect 47 (2014), 324–332.
28. 28 Sheng, W.H., Wang, J.T., Li, S.Y., Lin, Y.C., Cheng, A., Chen, Y.C., et al. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU. Diagn Microbiol Infect Dis 70 (2011), 380–386.
29. 29 Zhanel, G.G., Wiebe, R., Dilay, L., Rubinstein, E., Hoban, D.J., Noreddin, A.M., et al. Comparative review of the carbapenems. Drugs 67 (2007), 1027–1052.
30. 30 Roberts, J.A., Lipman, J., Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 37 (2009), 840–851.
31. 31 Bannerman, T.L., Hancock, G.A., Tenover, F.C., Miller, J.M., Pulse-field gel electrophoresis as a replacement for bacteriophage typing of Staphylococcus aureus. J Clin Microbiol 33 (1995), 551–555.
32. 32 Héritier, C., Poirel, L., Lambert, T., Nordmann, P., Contribution of acquired carbapenem-hydrolyzing oxacillinases to carbapenem resistance in Acinetobacter baumannii. Antimicrob Agents Chemother 49 (2005), 3198–3202.
33. 33 Lee, Y.T., Tsao, S.M., Hsueh, P.R., Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections. Eur J Clin Microbiol Infect Dis 32 (2013), 1211–1220.
34. 34 Burkhardt, O., Rauch, K., Kaever, V., Hadem, J., Kielstein, J.T., Welte, T., Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. Int J Antimicrob Agents 34 (2009), 101–102.
35. 35 Freire, A.T., Melnyk, V., Kim, M.J., Datsenko, O., Dzyublik, O., Glumcher, F., et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 68 (2010), 140–151.
36. 36 Bhavnani, S.M., Rubino, C.M., Hammel, J.P., Forrest, A., Dartois, N., Cooper, C.A., et al. Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. Antimicrob Agents Chemother 56 (2012), 1065–1072.
37. 37 Ramirez, J., Dartois, N., Gandjini, H., Yan, J.L., Korth-Bradley, J., McGovern, P.C., Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem–cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother 57 (2013), 1756–1762.
38. 38 Ambrose, P.G., Bhavnani, S.M., Ellis-Grosse, E.J., Drusano, G.L., Pharmacokinetic–pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap!. Clin Infect Dis 51 (2010), S103–S110.
39. 39 Sopirala, M.M., Mangino, J.E., Gebreyes, W.A., Biller, B., Bannerman, T., Balada-Llasat, J.M., et al. Synergy testing by E test, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 54 (2010), 4678–4683.
40. 40 Schafer, J.J., Goff, D.A., Stevenson, K.B., Mangino, J.E., Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy 27 (2007), 980–987.
41. 41 Chen, L.Y., Chen, T.C., Chen, Y.H., Lin, C.Y., Lin, W.R., Lu, P.L., Microbial isolation and emergence of antimicrobial resistance associated with tigecycline usage. J Microbiol Immunol Infect 44 (2011), 352–357.
42. 42 Cappelletty, D.M., Rybak, M.J., Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 40 (1996), 677–683.
43. 43 Jean, S.S., Hsueh, P.R., Current review of antimicrobial treatment of nosocomial pneumonia caused by multidrug-resistant pathogens. Expert Opin Pharmacother 12 (2011), 2145–2148.